Needham Reiterates Buy on Renovis

Analyst Mark Monane believes investors should focus on results of the pharmaceutical company's ischemic-stroke drug Cerovive

Needham reiterates Renovis (RNVS ) buy and has $18 12-month target.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.